HDAC6 and cancer: Histone deacetylase 6 (HDAC6) inhibition has potential as a novel strategy to prevent or reverse peripheral neuropathies induced by cisplatin, paclitaxel, or vincristine (Krukowski et al., 2017; Van Helleputte et al., 2018; Ma et al., 2019; J. Zhang et al., 2022); reversal is especially attractive as it does not interfere with the primary cancer treatment.